| |
Group 1
|
Group 2
|
Difference (95% CI)
|
p value
|
|---|
|
Age (years)
|
66.8 (±8.2)
|
71.8 (±8.7)
|
5.0 (1.2, 8.9)
|
0.012
|
|
TRUS volume (cm3)
|
76.1 (±35.0)
|
69.3 (±31.8)
|
8.5 (−24.1, 10.6)
|
0.402
|
|
PSA (ng/mL)
|
10.2 (±5.7)
|
5.0 (±3.9)
|
5.1 (2.5, 7.8)
|
< 0.001
|
|
Indication for HoLEP
|
|
LUTS
|
11 (45.8%)
|
34 (40.0%)
|
5.8 (−15.0, 27.3)
|
0.644
|
|
Refractory retention
|
13 (54.2%)
|
51 (60.0%)
| | |
|
Qmax (mL/sec)
|
9.9 (±4.3)
|
9.6 (±5.2)
|
0.4 (−3.0, 3.8)
|
0.817
|
|
PVR (mL)
|
181.4 (±99.6)
|
176.8 (±140.3)
|
4.6 (− 77.5, 86.8)
|
0.908
|
|
IPSS
|
22.4 (±4.7)
|
22.6 (±6.9)
|
0.2 (−3.7, 4.0)
|
0.923
|
|
Quality of life score
|
4.1 (±1.0)
|
4.4 (±1.2)
|
0.3 (−0.5, 1.1)
|
0.484
|
|
Serum creatinine (μmol/L)
|
81.0 (±16.0)
|
86.7 (±30.3)
|
5.7 (−3.5, 15.0)
|
0.219
|
- CI Confidence intervals, TRUS Trans-rectal ultrasound, PSA Prostate specific antigen, HoLEP Holmium laser enucleation of the prostate, LUTS Lower urinary tract symptoms, Qmax maximum flow rate, PVR Post-void residual volume, IPSS International Prostate Symptom Score. Data presented as mean (SD) except *counts (%).
